DENTSPLY SIRONA (XRAY) director reports 314.959 RSU dividend shares

Rhea-AI Filing Summary

DENTSPLY SIRONA Inc. director Brian T. Gladden reported receiving additional equity-linked compensation. On 01/09/2026, he acquired 314.959 shares of common stock at a price of $0, reported as directly owned. After this transaction, he beneficially owned 29,041.522 shares of DENTSPLY SIRONA common stock.

According to the footnote, these shares represent dividends on existing restricted stock units (RSUs), credited in the form of additional RSUs. These dividend RSUs carry the same vesting terms as the underlying RSU awards, vest simultaneously with them, and each RSU converts into one share of common stock.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Gladden Brian T

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	314.959	$0.00	--

Holdings After Transaction: Common Stock — 29,041.522 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Gladden Brian T

(Last) (First) (Middle)

C/O DENTSPLY SIRONA INC

13320-B BALLANTYNE CORPORATE PLACE

(Street)

CHARLOTTE NC 28277

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
DENTSPLY SIRONA Inc. [ XRAY ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
01/09/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/09/2026		A		314.959(1)	A	$0	29,041.522	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents dividends on restricted stock units (RSUs) awarded to the Reporting Person in the form of additional RSUs and are subject to the same vesting terms as the underlying awards. The dividends vest simultaneously with the RSUs to which they relate. Each RSU converts to common stock on a 1:1 basis.

	/s/ Jessica Nielsen Causey, Attorney-in-Fact for Brian T. Gladden	01/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Brian T. Gladden report for DENTSPLY SIRONA (XRAY)?

Director Brian T. Gladden reported acquiring 314.959 shares of DENTSPLY SIRONA common stock on 01/09/2026 at a price of $0, reported as directly owned.

How many DENTSPLY SIRONA (XRAY) shares does Brian T. Gladden own after this Form 4?

Following the reported transaction, Brian T. Gladden beneficially owned 29,041.522 shares of DENTSPLY SIRONA common stock.

What is the nature of the 314.959 shares reported in the XRAY Form 4 filing?

The 314.959 shares reflect dividends on restricted stock units (RSUs), credited as additional RSUs that follow the same vesting schedule as the original RSU awards.

Do the RSU dividend equivalents for XRAY vest separately from the underlying RSUs?

No. The filing states the dividend RSUs "vest simultaneously with the RSUs to which they relate," meaning they follow the same vesting timing as the underlying awards.

How do the RSUs reported in this DENTSPLY SIRONA (XRAY) Form 4 convert into shares?

Each RSU converts to DENTSPLY SIRONA common stock on a 1:1 basis, as disclosed in the footnote.

Was the insider XRAY transaction a purchase on the open market?

No. The 314.959 shares were acquired at a price of $0 as dividend equivalents on existing RSUs, not as an open-market purchase.